National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 58 of 66
Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)
NCT00341757
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
NCT00026689
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
NCT00020371
Vaccine Therapy in Treating Patients With Melanoma
NCT00020358
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00006473
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00007878
Micellar Paclitaxel to Treat Severe Psoriasis
NCT00006276
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00006929
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00006226
EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00006222
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
NCT00006171
Lung Screening Study
NCT00006382
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00019929
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
NCT00005967
SU5416 in Treating Patients With Malignant Mesothelioma
NCT00006014
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
NCT00006006
SU5416 and Carboplatin to Treat Ovarian Cancer
NCT00006155
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00006001
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
NCT00006228
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
NCT00006094
Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00020267
Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
NCT00006062
BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00006242
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
NCT00006102
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
NCT00006003
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
NCT00005916
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
NCT00005780
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
NCT00020176
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
NCT00019916
Voriconazole to Prevent Systemic Fungal Infections in Children
NCT00005912
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00020189
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
NCT00005908
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
NCT00020150
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
NCT00005842
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
NCT00020254
Celecoxib in Treating Patients With Bladder Cancer
NCT00006124
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
NCT00005961
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00020202
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
NCT00005843
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
NCT00005781
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
NCT00005976
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
NCT02210858
506U78 in Treating Patients With Lymphoma
NCT00005080
Thalidomide in Treating Patients With Myelofibrosis
NCT00015821
Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine
NCT00026676
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
NCT00006016
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
NCT00006015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.